-
Tekmira Announces Proposed Public Offering of Common Shares
-
Tekmira Announces Proposed Public Offering of Common Shares
-
Tekmira to Present at RBC Capital Markets' Healthcare Conference
-
Notable Analyst Rating Changes 1/13: (AAPL) (ETFC) (BBY) Upgraded; (ABT) (GHL) (HPQ) Downgraded
-
Tekmira Pharma (TKMR) Price Target Raised to $35 at RBC
-
Notable Analyst Rating Changes 10/6: (SPLK) (BDX) (COP) Upgraded; (TKMR) (MBLY) (NSM) Downgraded
-
RBC Lists 5 Catalysts for Tekmira (TKMR) And Only 1 is Ebola-Related
-
Tekmira (TKMR): Analyst Warns About Premature Excitement
-
Tekmira Pharma (TKMR) Remains Inexpensive, Says RBC
-
RBC Capital Starts Tekmira Pharma (TKMR) at Outperform
-
Tekmira Pharma (TKMR) Announces $60M Common Stock Offering
-
Tekmira Announces Proposed Public Offering of Common Stock
-
Webcast Advisory: Tekmira to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
-
Notable Analyst Rating Changes 01/31: (GIMO) (GLT) (JDSU) Upgraded; (CAM) (TIBX) (CRR) Downgraded

